High Prevalence of Potential Drug-Drug Interactions for Psoriasis Patients Prescribed Methotrexate or Cyclosporine for Psoriasis: Associated Clinical and Economic Outcomes in Real-World Practice

Publisher： Karger

E-ISSN： 1421-9832|220|2|128-137

ISSN： 1018-8665

Source： Dermatology, Vol.220, Iss.2, 2010-02, pp. : 128-137

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Switch to Biological Agent in Psoriasis Significantly Improved Clinical and Patient-Reported Outcomes in Real-World Practice

By  

Dermatology, Vol. 225, Iss. 4, 2013-01 ,pp. : 326-332

Karger

Access to resources Recommend Favorite

Real-World Outcome Analysis of Continuously and Intermittently Treated Patients with Moderate to Severe Psoriasis after Switching to a Biologic Agent

By  

Dermatology, Vol. 230, Iss. 4, 2015-02 ,pp. : 347-353

Karger

Access to resources Recommend Favorite

Evaluation of Topical Drug Treatment in Psoriasis

By  

Dermatology, Vol. 197, Iss. 1, 1998-07 ,pp. : 31-36

Karger

Access to resources Recommend Favorite

Medical History, Drug Exposure and the Risk of Psoriasis

By  

Dermatology, Vol. 216, Iss. 2, 2008-01 ,pp. : 125-132

Karger

Access to resources Recommend Favorite

Acute Severe Methotrexate Toxicity in Patients with Psoriasis: A Case Series and Discussion

By  

Dermatology, Vol. 229, Iss. 4, 2014-11 ,pp. : 306-309

Karger

Access to resources Recommend Favorite